Discovery Capabilities

Purposeful discovery, development and manufacturing of
innovative radiopharmaceuticals for solid tumors

Background

We are building a vertically integrated radiopharmaceutical therapeutics company with our lead program in a Phase 3 clinical trial. We believe we have established a leadership position in the emerging radiopharmaceutical therapeutics modality through a product-centric approach and have created a pipeline of multiple drug and development candidates in therapeutic areas with significant market opportunities.

Despite therapeutic advances made in the last decade, there remains a high unmet need for new cancer treatments. External beam radiation therapy is a proven approach to treating many cancers and is typically administered by an external beam of high energy rays. In contrast, radiopharmaceutical therapy (RPT) delivers radioisotopes to tumors intravenously.

We believe RPT represents one of the most promising new modalities for the treatment of solid tumors. Radiopharmaceuticals have the unique advantage of being both diagnostic and therapeutic. The same drug conjugate could be used for both diagnostic imaging and therapeutic use by switching out the radioisotope.

Conceptually, antibody drug conjugates, or ADCs, and RPT are similar in that they both consist of a binder recognizing a cancer protein target, linker, and payload to attack cancer cells. However, we believe certain aspects of RPT may offer advantages over ADCs on both efficacy and safety.

Discovery Capabilities

science-img-02

Our Data-Driven Workflow Drives Our Discovery Efforts

We believe RayzeBio is leading innovation in targeted radiopharmaceutical therapies. Our discovery engine and approach have allowed us to systematically evaluate over 20 targets involving over 500 in vivo experiments since our inception in 2020. Our state of the art 28,000 sq ft radiopharmaceutical research facility, based in San Diego, enables us to carry out all key aspects for discovery of novel drug candidates.

disc-cap-img

This center of excellence includes

  • Radiochemistry labeling lab for alpha and beta radioisotopes
  • Vivarium with molecular imaging and biodistribution analysis
  • Full in-vitro biological characterization
  • Small molecule and peptide chemistry capabilities
  • DMPK suite
Discovery Workflow

We prosecute diverse sets of binders against clinically validated cancer targets through an iterative process involving in-vitro screening, X-ray crystallography, linker and radiolabeling optimization, and in-vivo screening with molecular imaging and biodistribution analysis.
We have completed over 500 in vivo studies, which has provided us with broad proprietary and critical insights on identifying what we regards as key attributes essential in discovering novel RPT drug candidates.